Nestle’s incursion into the A1-free beta protein infant formula market in China is unlikely to damage NZX-listed a2 Milk Co’s prospects there, Harbour Asset Management senior analyst Oyvinn Rimer said.In a research note written…
Source: NZ Herald Business News